SecBot SecBot
SECBOTREPLAY Home › Report › BNTX

BNTX · BioNTech reported Q1 2026 revenue of €118.1M (down 35% YoY) and a GAAP…

BioNTech SE · PRESS-RELEASE filed May 5, 2026 at 06:45 ET

At the news

MIXEDIMPACT 6/10

PRESS-RELEASE filed May 5, 2026 at 06:45 ET

BioNTech reported Q1 2026 revenue of €118.1M (down 35% YoY) and a GAAP net loss of €531.9M (diluted EPS -€2.10), which beat the consensus EPS estimate of -$1.92 by ~35%. The company reaffirmed full-year 2026 revenue guidance of €2.0B-€2.3B and announced a planned $1B share repurchase program and a major manufacturing footprint consolidation expected to yield ~€500M in annual savings by 2029. However, the core COVID-19 vaccine business continues to decline, and the oncology pipeline, while advancing with multiple pivotal trial initiations, remains pre-commercial.

  • Q1 2026 revenue €118.1M vs €182.8M YoY (-35%), driven by lower COVID-19 vaccine sales
  • GAAP diluted EPS -€2.10 (-$2.46) vs consensus -$1.92, a 34.9% beat
  • Net loss widened to -€531.9M from -€415.8M YoY; adjusted net loss -€494.6M
  • Reaffirmed FY2026 revenue guidance €2.0B-€2.3B and adjusted R&D spend €2.2B-€2.5B

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access